SRPT:NGS-Sarepta Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 142.24

Change

-0.80 (-0.56)%

Market Cap

USD 1.99B

Volume

1.04M

Analyst Target

USD 193.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.52B
ARGX argenx NV ADR

N/A

USD 32.41B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.27B
MRNA Moderna Inc

N/A

USD 28.23B
BGNE BeiGene Ltd

N/A

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 17.44B
RPRX Royalty Pharma Plc

N/A

USD 17.14B
UTHR United Therapeutics Corporatio..

N/A

USD 15.72B
INSM Insmed Inc

N/A

USD 12.93B

ETFs Containing SRPT

PINK Simplify Exchange Traded .. 10.52 % 0.00 %

N/A

USD 0.24B
MSGR 6.12 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.11 % 0.00 %

N/A

N/A
XDNA:CA iShares Genomics Immunolo.. 4.54 % 0.00 %

N/A

CAD 5.18M
CURG:LSE VanEck Genomics and Healt.. 4.33 % 0.00 %

N/A

USD 6.97M
IBRN iShares Trust - iShares N.. 4.16 % 0.00 %

N/A

USD 3.84M
GN0M:XETRA Global X Genomics & Biote.. 3.92 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.92 % 0.00 %

N/A

USD 5.87M
GNOM Global X Genomics & Biote.. 3.92 % 0.00 %

N/A

USD 0.09B
GNOG:LSE Global X Genomics & Biote.. 3.84 % 0.00 %

N/A

USD 6.11M
BIOT:SW L&G Pharma Breakthrough U.. 3.00 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.84 % 0.00 %

N/A

USD 0.04B
WDNA:LSE WisdomTree BioRevolution .. 1.73 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 1.68 % 0.00 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 1.67 % 1.14 %

N/A

USD 1.01B
WRNA:XETRA WisdomTree BioRevolution .. 1.66 % 0.00 %

N/A

USD 2.77M
THNZ:XETRA L&G Global Thematic ESG E.. 0.80 % 0.00 %

N/A

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.77 % 0.00 %

N/A

N/A
AGED:SW iShares Ageing Population.. 0.68 % 0.00 %

N/A

N/A
USSMC:SW UBS (Irl) ETF plc - MSCI .. 0.60 % 0.00 %

N/A

N/A
CSY8:F Credit Suisse Index Fund .. 0.50 % 0.00 %

N/A

USD 0.55B
CSY8:XETRA UBS (Irl) ETF plc - MSCI .. 0.50 % 0.00 %

N/A

USD 0.55B
H41G:XETRA HSBC MSCI World Small Cap.. 0.39 % 0.00 %

N/A

N/A
VISM:AU Vanguard MSCI Internation.. 0.18 % 0.00 %

N/A

USD 0.29B
WOSC:SW SPDR® MSCI World Small C.. 0.17 % 0.00 %

N/A

USD 0.91B
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 0.00 %

N/A

N/A
LABS 0.00 % 0.45 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
ZPRS:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.83B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.00 %

N/A

USD 0.83B
PAMC Pacer Lunt MidCap Multi-F.. 0.00 % 0.00 %

N/A

USD 0.06B
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 47.51% 82% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.51% 82% B 90% A-
Trailing 12 Months  
Capital Gain 35.22% 77% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.22% 77% C+ 85% B
Trailing 5 Years  
Capital Gain -2.67% 70% C- 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.67% 70% C- 42% F
Average Annual (5 Year Horizon)  
Capital Gain 9.78% 68% D+ 68% D+
Dividend Return 9.78% 68% D+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.96% 59% D- 35% F
Risk Adjusted Return 20.38% 77% C+ 55% F
Market Capitalization 1.99B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 330.93 5% 4%
Price/Book Ratio 13.43 11% 8%
Price / Cash Flow Ratio -27.47 95% 91%
Price/Free Cash Flow Ratio -24.82 96% 91%
Management Effectiveness  
Return on Equity 2.02% 95% 62%
Return on Invested Capital -14.09% 83% 36%
Return on Assets -1.89% 94% 48%
Debt to Equity Ratio 131.79% 16% 17%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.